Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase.

Literature DB >> 11495357

Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase.

Abstract

Amyloid beta peptide implicated in Alzheimers disease is cleaved by insulin degrading enzyme (IDE). Abnormal cholinesterases similar to butyrylcholinesterase (BChE) are found in Alzheimer brain. The similarities between IDE and BChE (which is known to have an arylacylamidase and a metallocarboxypeptidase-like activity) such as their zinc metalloenzyme nature, their localization in glia and their ability to bind amyloid peptide in Alzheimers disease raise interesting questions.

Entities: Disease Gene

Mesh：

Substances：

Year: 2001 PMID： 11495357 DOI： 10.1023/a:1010967602362

Source DB: PubMed Journal: Neurochem Res ISSN： 0364-3190 Impact factor: 3.996

27 in total

1. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease.

Authors: D J Lehmann; Z Nagy; S Litchfield; M C Borja; A D Smith
Journal: Hum Genet Date: 2000-04 Impact factor: 4.132

2. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme.

Authors: K Vekrellis; Z Ye; W Q Qiu; D Walsh; D Hartley; V Chesneau; M R Rosner; D J Selkoe
Journal: J Neurosci Date: 2000-03-01 Impact factor: 6.167

3. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.

Authors: C I Wright; C Guela; M M Mesulam
Journal: Proc Natl Acad Sci U S A Date: 1993-01-15 Impact factor: 11.205

4. Alzheimer disease: an imbalance of proteolytic regulation?

Authors: M A Smith; G Perry
Journal: Med Hypotheses Date: 1994-04 Impact factor: 1.538

5. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K).

Authors: J M Grubber; A M Saunders; A R Crane-Gatherum; W K Scott; E R Martin; C S Haynes; P M Conneally; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal: Neurosci Lett Date: 1999-07-09 Impact factor: 3.046

6. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.

Authors: C I Wright; C Geula; M M Mesulam
Journal: Ann Neurol Date: 1993-09 Impact factor: 10.422

Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase.

1. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease.

2. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme.

3. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.

4. Alzheimer disease: an imbalance of proteolytic regulation?

5. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K).

6. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.

7. Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type.

8. Cholinesterases and the pathology of Alzheimer disease.

Review 9. Role of the beta-amyloid precursor protein in Alzheimer's disease.

Review 10. Identification of human plasma cholinesterase variants using molecular biological techniques.

Review 1. Insulin resistance and Alzheimer's disease.